 Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc FATE and Century Therapeutics Inc IPSC, an analyst at BofA Securities said in a note on Tuesday. The Biopharma Analyst: Tazeen Ahmad has a Buy rating and 112 price target on Fate shares. 